MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

Mind Cure Health Inc. has announced the signing of a non-binding letter of intent with Awakn Life Sciences, a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to better treat Addiction. The agreement with Awakn allows Mind Cure to to distribute its ketamine-assisted psychotherapy for Alcohol Use Disorder (AUD) protocol in the US and Canada.